Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.43 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13665490 | 0.93 | KDM4E (0.42) | KCNH2HTR5AKDM4EALDH1A1LMNA | |
| SCHEMBL13665759 | 0.90 | KDM4E (0.39) | KCNH2HTR5AKDM4EALDH1A1LMNA | |
| SCHEMBL13665487 | 0.88 | KDM4E (0.39) | KCNH2KDM4EALDH1A1LMNAGAA | |
| SCHEMBL13665775 | 0.88 | HTR6 (0.42) | KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL13665753 | 0.87 | SLC6A4 (0.40) | HTR5AKDM4EALDH1A1LMNAGAA | |
| SCHEMBL13665767 | 0.87 | MAPT (0.40) | KCNH2KDM4EALDH1A1LMNAGAA | |
| SCHEMBL13665755 | 0.85 | USP14 (0.43) | KCNH2KDM4EALDH1A1LMNAGAA | |
| SCHEMBL13666164 | 0.85 | KCNH2 (0.41) | KCNH2HTR5AKDM4EALDH1A1LMNA | |
| SCHEMBL13665495 | 0.85 | NR1I2 (0.36) | KCNH2HTR5AKDM4EALDH1A1LMNA | |
| SCHEMBL13654621 | 0.83 | HTR6 (0.47) | KCNH2HTR5AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338447-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | KCNH2 1610/4885HTR5A 6/4885KDM4E 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.